Inspired by viral replication, researchers developed a therapy that commandeers biological processes to craft nanoparticles within macrophages to aid in cancer therapy. Through self-assembly, the nanoparticles address some of the delivery
nanosynth’s Mark Duffin discusses what the company does, the Volz trial results, joint venture with a global wellness company and what investors can expect for the rest of the year in this exclusive interview with DirectorsTalk.
nanosynth Group plc (LON:NNN) CEO Mark Duffin joins DirectorsTalk Interviews to discuss its half yearly report for the six-month period ended 30 June 2022. Mark talks us through the trial results
nanosynth group plc (LON:NNN), the AIM quoted company specialising in the synthesis and application of nanoparticles to create new and improve existing products, has presented its unaudited half yearly report for the
Nanotechnology for Nutricosmetics Nanocarriers are ubiquitous within nanomedicine; however, with skin quality and health in high demand for consumers, these fields have overlapped. The use of nanotechnology and nanoformulations as
Nanotechnology is the science of manipulating atoms and molecules in the nanoscale – 80,000 times smaller than the width of a human hair. The world market for products that contain
nanosynth Group plc (LON:NNN), the AIM quoted company specialising in the synthesis and application of nanoparticles to create new and improve existing products, has announced successful trial results with Volz Holdings
Alzheimer’s disease (AD) is a complex neurodegenerative disease that leads to insidious deterioration of brain functions. Current treatments for AD that focus on inhibition of amyloid beta (Aβ) aggregation failed
Nanosynth Group plc (LON:NNN), the AIM quoted company specialising in the synthesis and application of nanoparticles to create new and improve existing products, has announced they have entered into a joint
nanosynth Group plc (LON:NNN), the AIM quoted company specialising in the synthesis and application of nanoparticles to create new and improve existing products, has announced a conditional subscription to raise £2,942,500
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
